Illia Petrov

Servier, an international pharmaceutical group, and Google Cloud have announced a five-year extension of their collaboration to integrate AI technologies across Servier's R&D, production, and distribution activities. This partnership aims to address challenges in drug development, which currently takes an average of 15 years, by using AI to analyze large datasets, streamline clinical trials, and optimize drug formulations.

A28 Therapeutics, a clinical-stage biopharmaceutical company, and GATC Health Corp, a developer of AI-driven drug discovery tools, have announced the completion of an AI-based analysis of A28’s lead drug candidate, AT-101. This analysis was conducted to evaluate the drug’s efficacy, safety, and potential off-target effects, with the goal of supporting clinical trial optimization and minimizing development risks. The announcement was made during the J.P. Morgan Healthcare Conference.

Researchers at CCM Biosciences, a New Jersey-based biopharmaceutical company, have reported the discovery of first-in-class compounds designed to restore the activity of SIRT3, a mitochondrial enzyme critical to cellular energy production and aging processes. Published in Physical Review X, this study introduces a novel mechanism of enzyme activation, bypassing the limitations of traditional allosteric modulation methods.

Profluent Bio, a Berkeley-based biotech founded in 2022, and funded with $44 million to date, has released an AI model aimed at advancing the design of CRISPR-Cas gene-editing systems. The company's latest research, published in a preprint on January 6th, 2025, demonstrates how deep learning can be harnessed to expand the genome-editing potential of CRISPR complexes by tailoring their DNA recognition capabilities.

FTI Consulting’s Healthcare & Life Sciences Outlook Survey surveyed 250 U.S.-based decision-makers from corporate communications, investor relations, public affairs, business development, and marketing roles in healthcare and life sciences companies. Conducted online between September 24 and October 9, 2024, the survey provides insights into industry optimism, challenges, and investment priorities.

Just two months after raising $120 million to advance its AI-driven tNova platform and internal immunology programs, Terray Therapeutics has secured a new research partnership with Gilead Sciences. The collaboration focuses on discovering and developing novel small molecule therapies across multiple therapeutic targets identified by Gilead.

Following its recent expansion into Japan, Lantern Pharma has now dosed the first patient in Taiwan as part of its Phase 2 Harmonic clinical trial., evaluating LP-300 in never-smoker non-small cell lung cancer (NSCLC) patients who have relapsed after tyrosine kinase inhibitor (TKI) therapy.

In the rapidly changing field of clinical trials, chatbots are becoming valuable tools for data analysis. These AI-driven conversational agents streamline data collection, boost patient engagement, and enhance the accuracy of data management. By automating interactions with patients, chatbots ensure consistent and precise data collection, reducing human error and operational costs. They also provide real-time insights, allowing researchers to monitor trial progress and make timely adjustments.

Despite these benefits, challenges such as biases in AI algorithms, lack of standardization, and usability issues persist. The accuracy of chatbots is influenced by the quality of data and the sophistication of machine learning algorithms. Nevertheless, their potential to transform clinical trial data analysis is considerable, offering scalable, cost-effective solutions that improve patient experience and data reliability. Future advancements in AI and machine learning, along with rigorous validation and standardization, will be crucial for the successful integration of chatbots into clinical trial processes.

This blog post explores the advantages, challenges, and future prospects of using chatbots in clinical trial data analysis, providing a thorough overview of their current and potential impact on the field.

Covid 19 pandemic that we went through revealed the fragility of our world. Despite the undeniable technological advancements of the past century, the challenges we are facing are still numerous and require immediate action. The midway report on Sustainable Development Goals released by the UN in 2023 showed that out of ca. 140 measurable targets, 50% show moderate or severe deviations from the desired trajectory and more than 30% have experienced no progress or regression below the 2015 baseline.

Xcell Biosciences, Inc., a notable company in the field of cell and gene therapy applications, has recently unveiled a strategic partnership with ElevateBio, LLC. This collaboration is set to explore innovative methods to augment the therapeutic efficacy of cell and gene therapies. A key highlight of this alliance is ElevateBio's induction as the inaugural participant in Xcellbio’s AVATAR Foundry™ beta program. Moreover, the partnership is strengthened by the appointment of Michael Paglia, Chief Technology Officer at ElevateBio’s BaseCamp®, to Xcellbio’s Scientific Advisory Board.